Risk of New-Onset Psoriasis Associated With TNF-α Inhibitor Treatment in Patients With Immune-Mediated Inflammatory Diseases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Absolute and Relative Risk of New-Onset Psoriasis Associated With Tumor Necrosis Factor-α Inhibitor Treatment in Patients With Immune-Mediated Inflammatory Diseases: A Danish Nationwide Cohort Study
JAMA Dermatol 2022 Jun 29;[EPub Ahead of Print], D Thein, A Egeberg, L Skov, N LoftFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.